Cyclerion Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for serious diseases. Co.'s portfolio includes soluble guanylate cyclase (sGC) stimulators that modulate a key node in a fundamental signaling network in both the central nervous system (CNS) and the periphery. The nitric oxide (NO) sGC cyclic guanosine monophosphate (cGMP) signaling pathway is a fundamental mechanism that controls key aspects of physiology throughout the body. The NO-sGC-cGMP pathway regulates biological functions including mitochondrial function, neuronal function, inflammation, and hemodynamics. We show 21 historical shares outstanding datapoints in our CYCN shares outstanding history coverage, used to compute CYCN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CYCN market cap history over the course of time is important for investors
interested in comparing CYCN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CYCN versus a peer is one thing; comparing
CYCN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CYCN can fluctuate over the course of history.
With this page we aim to empower investors researching CYCN by allowing them to research the CYCN market cap history. |
Free CYCN Email Alerts:
Video: The Importance of Market Cap
